Interaction between thrombin mutant W215A/E217A and direct thrombin inhibitor

Blood Coagulation and Fibrinolysis

Volumn 19, Issue 5, 2008, Pages 465-468

  Tanaka, Kenichi A ^a   Gruber, Andras ^b   Szlam, Fania ^a   Bush, Leslie A ^c   Hanson, Stephen R ^b   Di Cera, Enrico ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; FIBRINOGEN; HIRULOG; LEPIRUDIN; MUTANT PROTEIN; PROTEIN C; THROMBIN; THROMBOMODULIN;

ANTICOAGULATION; BINDING AFFINITY; CATALYST; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG BINDING; HYDROLYSIS; LETTER; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; WILD TYPE;

AMINO ACID SUBSTITUTION; ANTICOAGULANTS; ENZYME INHIBITORS; FIBRINOGEN; HUMANS; MUTATION, MISSENSE; PIPECOLIC ACIDS; PROTEIN BINDING; PROTEIN C; PROTEIN STRUCTURE, TERTIARY; THROMBIN;

EID: 67649532171     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328304e044     Document Type: Letter

References (13)

1. Cantwell AM, Di Cera E. Rational design of a potent anticoagulant thrombin. J Biol Chem 2000; 275:39827-39830.
2. Gruber A, Cantwell AM, Di Cera E, Hanson SR. The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo. J Biol Chem 2002; 277:27581-27584.
3. Pineda AO, Chen ZW, Caccia S, Cantwell AM, Savvides SN, Waksman G, et al. The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket. J Biol Chem 2004; 279:39824-39828.
4. Elg M, Gustafsson D, Deinum J. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb Haemost 1997; 78:1286-1292.
5. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33:4-15.
6. Adams TE, Everse SJ, Mann KG. Predicting the pharmacology of thrombin inhibitors. J Thromb Haemost 2003; 1:1024-1027.
7. Krem MM, Di Cera E. Dissecting substrate recognition by thrombin using the inactive mutant S195A. Biophys Chem 2003; 100:315-323.
8. Sakurai Y, Shima M, Giddings J, Takeyama M, Kasuda S, Nogami K, et al. A critical role for thrombin in platelet aggregation under high shear stress. Thromb Res 2004; 113:311-318.
9. Myles T, Yun TH, Hall SW, Leung LL. An extensive interaction interface between thrombin and factor V is required for factor V activation. J Biol Chem 2001; 276:25143-25149.
10. Bostrom SL, Dagnelid E, Hansson GFH, Ulvinge C. Inhibition of thrombin-induced feedback activation of factor V: a potential pathway for inhibition of thrombin generation by melagatran. Blood Coagul Fibrinolysis 2004; 15:25-30.
11. Butenas S, Orfeo T, Brummel-Ziedins KE, Mann KG. Influence of bivalirudin on tissue factor-triggered coagulation. Blood Coagul Fibrinolysis 2007; 18:407-414.
12. Tanaka KA, Szlam F, Levy JH. The effect of aprotinin on activated protein C-mediated downregulation of endogenous thrombin generation. Br J Haematol 2006; 134:77-82.
13. Tanaka K, Szlam F, Katori N, Sato N, Vega J, Levy J. The effects of argatroban on thrombin generation and hemostatic activation in vitro. Anesth Analg 2004; 99:1283-1289.